Anne Fish-Steagall1, Polly Searcy, Rebecca Sipples. 1. Division of Hematology/Oncology, University of North Carolina at Chapel Hill, 3009 Old Clinic Building, Chapel Hill, NC 27599, USA. afs@med.unc.edu
Abstract
OBJECTIVES: To review clinical experience and studies with anti-EGFR therapies in metastatic CRC, SCCHN, and NSCLC. Case studies in each tumor type will also be outlined. DATA SOURCES: Research articles and patient case histories. CONCLUSION: Several phase II/III trials have shown the activity of anti-EGFR therapy in CRC, SCCHN, and NSCLC. Treatment confers substantial clinical benefit with improved symptoms, particularly in previously treated patients. Toxicity of anti-EGFR therapies is generally manageable and non-overlapping with other treatment options, including chemotherapy and radiotherapy. IMPLICATIONS FOR NURSING PRACTICE: It is important for nurses to further advance our understanding of anti-EGFR therapies and continue to encourage patient enrollment in ongoing trials of anti-EGFR therapy.
OBJECTIVES: To review clinical experience and studies with anti-EGFR therapies in metastatic CRC, SCCHN, and NSCLC. Case studies in each tumor type will also be outlined. DATA SOURCES: Research articles and patient case histories. CONCLUSION: Several phase II/III trials have shown the activity of anti-EGFR therapy in CRC, SCCHN, and NSCLC. Treatment confers substantial clinical benefit with improved symptoms, particularly in previously treated patients. Toxicity of anti-EGFR therapies is generally manageable and non-overlapping with other treatment options, including chemotherapy and radiotherapy. IMPLICATIONS FOR NURSING PRACTICE: It is important for nurses to further advance our understanding of anti-EGFR therapies and continue to encourage patient enrollment in ongoing trials of anti-EGFR therapy.
Authors: Ling Xu; Martin Hausmann; Wolfgang Dietmaier; Silvia Kellermeier; Theresa Pesch; Manuela Stieber-Gunckel; Elisabeth Lippert; Frank Klebl; Gerhard Rogler Journal: BMC Cancer Date: 2010-06-18 Impact factor: 4.430